Our in vitro tests show that targeting KAT7 by a specific inhibitor WM-383561 or HLEDR by ASOs synergistically enhanced cytotoxicity of the EGFR inhibitor Erlotinib in GBM cells. Here, KAT7 is linked to glioblastoma.